GlassScriptPhysician profile
David Sharrah
NPI 1083005904
$10,337.36
in general payments reported to CMS, 2019-2025
20 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $312 · 2021: $2,626 · 2022: $2,688 · 2023: $2,157 · 2024: $1,883 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961 · Travel and Lodging: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,960.63 |
| Travel and Lodging | $1,751.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,009.06 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Spinal Simplicity, LLC | $1,825.03 | 2021 | |
| Relievant Medsystems, INC. | $1,635.70 | 2022 | |
| Boston Scientific Corporation | $1,603.01 | 2021-2023 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16 |
| Nalu Medical, INC. | $874.37 | 2022 | |
| Medtronic USA, INC. | $312.21 | 2020 | |
| Collegium Pharmaceutical, INC. | $233.50 | 2022-2025 | Belbuca |
| Abbott Laboratories | $158.74 | 2023-2025 | Eterna, Proclaim |
| Saluda Medical Americas, INC. | $155.22 | 2022-2025 | Evoke Scs, Evoke |
| Spr Therapeutics, INC | $141.43 | 2023-2025 | Sprint Pns System |
| Forte Bio-Pharma LLC | $131.30 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Merck Sharp & Dohme LLC | $54.58 | 2023 | Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.58 | 2023-2024 | Relistor |
| Averitas Pharma INC. | $46.30 | 2023-2024 | Qutenza |
| Almatica Pharma LLC | $27.26 | 2021-2023 | Gralise |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $16.19 | 2023 | Tirosint, Licart |
| Scilex Pharmaceuticals INC. | $16.16 | 2023 | Ztlido |
| Appliedvr INC | $15.26 | 2025 | Relievrx |
| Valinor Pharma, LLC | $15.20 | 2025 | Movantik |
| Kowa Pharmaceuticals America, INC. | $13.26 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sharrah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.